359 related articles for article (PubMed ID: 25294908)
1. Identification of recurrent FGFR3-TACC3 fusion oncogenes from lung adenocarcinoma.
Capelletti M; Dodge ME; Ercan D; Hammerman PS; Park SI; Kim J; Sasaki H; Jablons DM; Lipson D; Young L; Stephens PJ; Miller VA; Lindeman NI; Munir KJ; Richards WG; Jänne PA
Clin Cancer Res; 2014 Dec; 20(24):6551-8. PubMed ID: 25294908
[TBL] [Abstract][Full Text] [Related]
2. Emergence of FGFR3-TACC3 fusions as a potential by-pass resistance mechanism to EGFR tyrosine kinase inhibitors in EGFR mutated NSCLC patients.
Ou SI; Horn L; Cruz M; Vafai D; Lovly CM; Spradlin A; Williamson MJ; Dagogo-Jack I; Johnson A; Miller VA; Gadgeel S; Ali SM; Schrock AB
Lung Cancer; 2017 Sep; 111():61-64. PubMed ID: 28838400
[TBL] [Abstract][Full Text] [Related]
3. FGFR1/3 tyrosine kinase fusions define a unique molecular subtype of non-small cell lung cancer.
Wang R; Wang L; Li Y; Hu H; Shen L; Shen X; Pan Y; Ye T; Zhang Y; Luo X; Zhang Y; Pan B; Li B; Li H; Zhang J; Pao W; Ji H; Sun Y; Chen H
Clin Cancer Res; 2014 Aug; 20(15):4107-14. PubMed ID: 24850843
[TBL] [Abstract][Full Text] [Related]
4. FGFR3-TACC3 is an oncogenic fusion protein in respiratory epithelium.
Best SA; Harapas CR; Kersbergen A; Rathi V; Asselin-Labat ML; Sutherland KD
Oncogene; 2018 Nov; 37(46):6096-6104. PubMed ID: 29991799
[TBL] [Abstract][Full Text] [Related]
5. Detection, Characterization, and Inhibition of FGFR-TACC Fusions in IDH Wild-type Glioma.
Di Stefano AL; Fucci A; Frattini V; Labussiere M; Mokhtari K; Zoppoli P; Marie Y; Bruno A; Boisselier B; Giry M; Savatovsky J; Touat M; Belaid H; Kamoun A; Idbaih A; Houillier C; Luo FR; Soria JC; Tabernero J; Eoli M; Paterra R; Yip S; Petrecca K; Chan JA; Finocchiaro G; Lasorella A; Sanson M; Iavarone A
Clin Cancer Res; 2015 Jul; 21(14):3307-17. PubMed ID: 25609060
[TBL] [Abstract][Full Text] [Related]
6. FGFR3-TACC3 fusion proteins act as naturally occurring drivers of tumor resistance by functionally substituting for EGFR/ERK signaling.
Daly C; Castanaro C; Zhang W; Zhang Q; Wei Y; Ni M; Young TM; Zhang L; Burova E; Thurston G
Oncogene; 2017 Jan; 36(4):471-481. PubMed ID: 27345413
[TBL] [Abstract][Full Text] [Related]
7. Recurrent FGFR3-TACC3 fusion gene in nasopharyngeal carcinoma.
Yuan L; Liu ZH; Lin ZR; Xu LH; Zhong Q; Zeng MS
Cancer Biol Ther; 2014; 15(12):1613-21. PubMed ID: 25535896
[TBL] [Abstract][Full Text] [Related]
8. Genomic Profiling of Circulating Tumor DNA in Relapsed EGFR-mutated Lung Adenocarcinoma Reveals an Acquired FGFR3-TACC3 Fusion.
Allen JM; Schrock AB; Erlich RL; Miller VA; Stephens PJ; Ross JS; Ou SI; Ali SM; Vafai D
Clin Lung Cancer; 2017 May; 18(3):e219-e222. PubMed ID: 28089157
[No Abstract] [Full Text] [Related]
9. Detection of Known and Novel FGFR Fusions in Non-Small Cell Lung Cancer by Comprehensive Genomic Profiling.
Qin A; Johnson A; Ross JS; Miller VA; Ali SM; Schrock AB; Gadgeel SM
J Thorac Oncol; 2019 Jan; 14(1):54-62. PubMed ID: 30267839
[TBL] [Abstract][Full Text] [Related]
10. Oncogenic Gene Fusion FGFR3-TACC3 Is Regulated by Tyrosine Phosphorylation.
Nelson KN; Meyer AN; Siari A; Campos AR; Motamedchaboki K; Donoghue DJ
Mol Cancer Res; 2016 May; 14(5):458-69. PubMed ID: 26869289
[TBL] [Abstract][Full Text] [Related]
11. Non-Small Cell Lung Carcinoma With Clear Cell Features and FGFR3::TACC3 Gene Rearrangement : Clinicopathologic and Next Generation Sequencing Study of 7 Cases.
Suster D; Mackinnon AC; Ronen N; Mejbel HA; Harada S; Suster S
Am J Surg Pathol; 2024 Mar; 48(3):284-291. PubMed ID: 38084010
[TBL] [Abstract][Full Text] [Related]
12. Development of RNA-FISH Assay for Detection of Oncogenic FGFR3-TACC3 Fusion Genes in FFPE Samples.
Kurobe M; Kojima T; Nishimura K; Kandori S; Kawahara T; Yoshino T; Ueno S; Iizumi Y; Mitsuzuka K; Arai Y; Tsuruta H; Habuchi T; Kobayashi T; Matsui Y; Ogawa O; Sugimoto M; Kakehi Y; Nagumo Y; Tsutsumi M; Oikawa T; Kikuchi K; Nishiyama H
PLoS One; 2016; 11(12):e0165109. PubMed ID: 27930669
[TBL] [Abstract][Full Text] [Related]
13. Drug-sensitive FGFR3 mutations in lung adenocarcinoma.
Chandrani P; Prabhash K; Prasad R; Sethunath V; Ranjan M; Iyer P; Aich J; Dhamne H; Iyer DN; Upadhyay P; Mohanty B; Chandna P; Kumar R; Joshi A; Noronha V; Patil V; Ramaswamy A; Karpe A; Thorat R; Chaudhari P; Ingle A; Choughule A; Dutt A
Ann Oncol; 2017 Mar; 28(3):597-603. PubMed ID: 27998968
[TBL] [Abstract][Full Text] [Related]
14. Transforming fusions of FGFR and TACC genes in human glioblastoma.
Singh D; Chan JM; Zoppoli P; Niola F; Sullivan R; Castano A; Liu EM; Reichel J; Porrati P; Pellegatta S; Qiu K; Gao Z; Ceccarelli M; Riccardi R; Brat DJ; Guha A; Aldape K; Golfinos JG; Zagzag D; Mikkelsen T; Finocchiaro G; Lasorella A; Rabadan R; Iavarone A
Science; 2012 Sep; 337(6099):1231-5. PubMed ID: 22837387
[TBL] [Abstract][Full Text] [Related]
15. FGFR3-TACC3 fusion in solid tumors: mini review.
Costa R; Carneiro BA; Taxter T; Tavora FA; Kalyan A; Pai SA; Chae YK; Giles FJ
Oncotarget; 2016 Aug; 7(34):55924-55938. PubMed ID: 27409839
[TBL] [Abstract][Full Text] [Related]
16. Identification of recurrent FGFR3 fusion genes in lung cancer through kinome-centred RNA sequencing.
Majewski IJ; Mittempergher L; Davidson NM; Bosma A; Willems SM; Horlings HM; de Rink I; Greger L; Hooijer GK; Peters D; Nederlof PM; Hofland I; de Jong J; Wesseling J; Kluin RJ; Brugman W; Kerkhoven R; Nieboer F; Roepman P; Broeks A; Muley TR; Jassem J; Niklinski J; van Zandwijk N; Brazma A; Oshlack A; van den Heuvel M; Bernards R
J Pathol; 2013 Jul; 230(3):270-6. PubMed ID: 23661334
[TBL] [Abstract][Full Text] [Related]
17. Oncogenic driver FGFR3-TACC3 requires five coiled-coil heptads for activation and disulfide bond formation for stability.
Wang CG; Peiris MN; Meyer AN; Nelson KN; Donoghue DJ
Oncotarget; 2023 Feb; 14():133-145. PubMed ID: 36780330
[TBL] [Abstract][Full Text] [Related]
18. Comparison of targeted next-generation sequencing with conventional sequencing for predicting the responsiveness to epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy in never-smokers with lung adenocarcinoma.
Han JY; Kim SH; Lee YS; Lee SY; Hwang JA; Kim JY; Yoon SJ; Lee GK
Lung Cancer; 2014 Aug; 85(2):161-7. PubMed ID: 24857785
[TBL] [Abstract][Full Text] [Related]
19. Dual targeting of FGFR3 and ERBB3 enhances the efficacy of FGFR inhibitors in FGFR3 fusion-driven bladder cancer.
Weickhardt AJ; Lau DK; Hodgson-Garms M; Lavis A; Jenkins LJ; Vukelic N; Ioannidis P; Luk IY; Mariadason JM
BMC Cancer; 2022 May; 22(1):478. PubMed ID: 35501832
[TBL] [Abstract][Full Text] [Related]
20. Clinical characteristics of patients with non-small cell lung cancers harboring anaplastic lymphoma kinase rearrangements and primary lung adenocarcinoma harboring epidermal growth factor receptor mutations.
Xu L; Lei J; Wang QZ; Li J; Wu L
Genet Mol Res; 2015 Oct; 14(4):12973-83. PubMed ID: 26505450
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
